The daily cost of ICU patients: A micro-costing study in 23 French Intensive Care Units
- PMID: 25986476
- DOI: 10.1016/j.accpm.2014.09.004
The daily cost of ICU patients: A micro-costing study in 23 French Intensive Care Units
Abstract
Objectives: To estimate the daily cost of intensive care unit (ICU) stays via micro-costing.
Methods: A multicentre, prospective, observational, cost analysis study was carried out among 21 out of 23 French ICUs randomly selected from French National Hospitals. Each ICU randomly enrolled 5 admitted adult patients with a simplified acute physiology II score ≥ 15 and with at least one major intensive care medical procedure. All health-care human resources used by each patient over a 24-hour period were recorded, as well as all medications, laboratory analyses, investigations, tests, consumables and administrative expenses. All resource costs were estimated from the hospital's perspective (reference year 2009) based on unitary cost data.
Results: One hundred and four patients were included (mean age: 62.3 ± 14.9 years, mean SAPS II: 51.5 ± 16.1, mean SOFA on the study day: 6.9 ± 4.3). Over 24 hours, 29 to 186 interventions per patient were performed by different caregivers, leading to a mean total time spent for patient care of 13:32 ± 05:00 h. The total daily cost per patient was € 1425 ± € 520 (95% CI = € 1323 to € 1526). ICU human resources represented 43% of total daily cost. Patient-dependent expenses (€ 842 ± € 521) represented 59% of the total daily cost. The total daily cost was correlated with the daily SOFA score (r = 0.271, P = 0.006) and the bedside-time given by caregivers (r = 0.716, P < 0.0001).
Conclusion: The average cost of one day of ICU care in French National Hospitals is strongly correlated with the duration of bedside-care carried out by human resources.
Keywords: Cost; ICU.
Copyright © 2015. Published by Elsevier Masson SAS.
Similar articles
-
A multicentre, prospective study to evaluate costs of septic patients in Brazilian intensive care units.Pharmacoeconomics. 2008;26(5):425-34. doi: 10.2165/00019053-200826050-00006. Pharmacoeconomics. 2008. PMID: 18429658
-
A German national prevalence study on the cost of intensive care: an evaluation from 51 intensive care units.Crit Care. 2007;11(3):R69. doi: 10.1186/cc5952. Crit Care. 2007. PMID: 17594475 Free PMC article.
-
[Cost of intensive care in a German hospital: cost-unit accounting based on the InEK matrix].Anaesthesist. 2008 May;57(5):505-12. doi: 10.1007/s00101-008-1353-7. Anaesthesist. 2008. PMID: 18389191 German.
-
Cost-utility in medical intensive care patients. Rationalizing ongoing care and timing of discharge from intensive care.Ann Am Thorac Soc. 2015 Jul;12(7):1058-65. doi: 10.1513/AnnalsATS.201411-527OC. Ann Am Thorac Soc. 2015. PMID: 26011090
-
Analysis of resource use and cost-generating factors in a German medical intensive care unit employing the Therapeutic Intervention Scoring System (TISS-28).Intensive Care Med. 2002 Mar;28(3):324-31. doi: 10.1007/s00134-001-1201-6. Epub 2002 Feb 1. Intensive Care Med. 2002. PMID: 11904663
Cited by
-
Renal replacement anticoagulant management: Protocol and analysis plan for an observational comparative effectiveness study of linked data sources.J Intensive Care Soc. 2022 Aug;23(3):311-317. doi: 10.1177/1751143720913417. Epub 2020 Apr 2. J Intensive Care Soc. 2022. PMID: 36033243 Free PMC article.
-
Neuroprotection of NSC Therapy is Superior to Glibenclamide in Cardiac Arrest-Induced Brain Injury via Neuroinflammation Regulation.Transl Stroke Res. 2022 Aug 3. doi: 10.1007/s12975-022-01047-y. Online ahead of print. Transl Stroke Res. 2022. PMID: 35921049
-
Heparin versus citrate anticoagulation for continuous renal replacement therapy in intensive care: the RRAM observational study.Health Technol Assess. 2022 Feb;26(13):1-58. doi: 10.3310/ZXHI9396. Health Technol Assess. 2022. PMID: 35212260 Free PMC article.
-
ICU-Associated Costs during the Fourth Wave of the COVID-19 Pandemic in a Tertiary Hospital in a Low-Vaccinated Eastern European Country.Int J Environ Res Public Health. 2022 Feb 4;19(3):1781. doi: 10.3390/ijerph19031781. Int J Environ Res Public Health. 2022. PMID: 35162804 Free PMC article.
-
Health Economic Aspects of Chimeric Antigen Receptor T-cell Therapies for Hematological Cancers: Present and Future.Hemasphere. 2021 Jan 28;5(2):e524. doi: 10.1097/HS9.0000000000000524. eCollection 2021 Feb. Hemasphere. 2021. PMID: 33880433 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
